Skip to content
OpenCapital
Get started

BioCryst Pharmaceuticals BCRX EV / EBITDA

EV / EBITDA at other companies

ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
8.1×-16.2×
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
32.6×—
Arrowhead Research logo
Arrowhead ResearchARWR
27.4×—
Acadia Pharmaceuticals logo
Acadia PharmaceuticalsACAD
38.4×+27.9×
HRO
HarrowHROW
70.8×-139×
ALN
Alnylam PharmaceuticalsALNY
52.6×—

Other financials

Income statement

See full
Revenue$156.4M+7.5%
Gross profit$151.0M+7.1%
Operating income-$701.6M-3,405%
Net income-$721.8M-2,255,763%
EPS (diluted)-$2.98—

Balance sheet

See full
Cash & equivalents$173.4M+62.2%
Total debt$411.8M+24.7%
Total equity-$553.8M-22.6%
Total assets$465.1M-3.1%

Cash flow

See full
Operating cash flow-$61.8M-125%
CapEx$403.0K+182%
Free cash flow-$62.2M-125%

Valuation

See full
Market cap$2.37B+52.3%
Enterprise value$2.6B+46.7%
P/S2.7×-0.4×

Profitability

See full
Gross margin97.8%+0.8pp
Operating margin-43.1%-49.7pp
Net margin-51.7%-69.7pp
FCF margin35%—

Returns & leverage

See full
Return on equity-882.8%—
Debt / equity0.1×—
Current ratio1.9×-1.0×

Where this comes from

Calculated from BioCryst Pharmaceuticals’s reported figures.

enterprise value/ebitda=4.6×

Based on the most recent quarter.

The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about BioCryst Pharmaceuticals's ev / ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is BioCryst Pharmaceuticals's EV / EBITDA?
BioCryst Pharmaceuticals (BCRX) reported EV / EBITDA of 4.6× in Q4 2025.
What does EV / EBITDA mean?
Enterprise value (market cap plus total debt minus cash) at the quarter end divided by trailing-twelve-month EBITDA. A capital-structure-neutral valuation multiple.